Piracetam and the other racetams, noopept (omberacetam) and phenibut are not lawful dietary ingredients in the United States. They are drugs — one licensed in parts of Europe, one a Russian prescription medicine, one a Soviet-era anxiolytic — and none of them meets the statutory definition of something a dietary supplement may contain. FDA has said so directly for phenibut and has issued warning letters to nootropic sellers on the same basis, including to Peak Nootropics LLC on 5 February 2019. A 2020 analysis in Neurology: Clinical Practice tested US “cognitive enhancement” supplements and found five unapproved drugs in them — omberacetam, aniracetam, phenibut, vinpocetine and picamilon — frequently at doses above pharmacological norms and frequently undeclared.
The claim
Go looking for “real” nootropics — the ones people describe as a step beyond the capsules sold in pharmacies — and you land in the same place every time. Piracetam is presented as the original, the compound that gave the category its name. Phenylpiracetam is the one athletes whisper about. Noopept arrives with a number attached: a thousand times more potent than piracetam. Phenibut is sold as the social-anxiety one, the thing that makes conversation effortless.
The framing throughout is that these are simply less famous supplements — grey-market, sure, but fundamentally the same kind of thing as fish oil, and safer than a prescription because no doctor was involved. Every part of that is wrong. These are pharmaceuticals with prescribing histories, dose-response curves and withdrawal syndromes, sold under a legal framework designed for vitamins.
Where they came from
Piracetam was synthesized by Corneliu Giurgea in 1964, and it is the compound for which he coined the word “nootropic.” It has been licensed as a drug in parts of Europe ever since, which is where its reputation comes from. Aniracetam, oxiracetam, pramiracetam and phenylpiracetam followed, mostly through Italian and Eastern-European development programmes, and each has progressively thinner human data than the one before it.
Noopept — chemically N-phenylacetyl-L-prolylglycine ethyl ester, developed as GVS-111 — is a Russian prescription drug. Essentially all of its human data are Russian, published in Russian-language journals, methodologically opaque and unavailable for independent scrutiny. Phenibut came out of the same Soviet pharmacological tradition and was used clinically as an anxiolytic.
None of that history is disputed. It is also not a licence. A compound being a legal medicine in one country tells you nothing about whether it may lawfully be sold in the US as a supplement, and in these cases the answer is that it may not.
What the regulatory record actually says
| Compound | What it actually is | US status | Evidence in healthy adults |
|---|---|---|---|
| Piracetam | Licensed drug in parts of Europe; the original “nootropic” (Giurgea, 1964) | Not an approved US drug and not a lawful dietary ingredient; FDA warning letters issued | Essentially absent. Its Cochrane review in dementia and cognitive impairment concluded the evidence does not support its use |
| Aniracetam, oxiracetam, pramiracetam | Older Italian and Eastern-European development compounds | Not lawful dietary ingredients | Progressively thinner than piracetam’s; mostly old, small trials |
| Phenylpiracetam | Racetam derivative | Not a lawful dietary ingredient; also on WADA’s prohibited list | Inadequately characterized in humans |
| Noopept (omberacetam) | Russian prescription drug | Not a vitamin, mineral, herb, amino acid or dietary substance, therefore not a lawful dietary ingredient | No adequate, independently replicated human RCT showing cognitive benefit |
| Phenibut | Soviet-era anxiolytic | FDA states explicitly that it does not meet the statutory definition of a dietary ingredient; products declaring it are misbranded | Not the relevant question — dependence and withdrawal are |
FDA’s enforcement record here is public. Warning letters went to nootropic sellers on the ingredient-status basis, including Peak Nootropics LLC, also trading as Advanced Nootropics, on 5 February 2019.2 On phenibut specifically, FDA published its position that the substance does not meet the statutory definition of a dietary ingredient, issued warning letters in April 2019 to Atomixx, Evol Nutrition and NeuroScience, and obtained a permanent injunction against the seller of a product called Chill6 in June 2023.3 The same posture applies to vinpocetine, which FDA addressed in a Federal Register notice in September 2016 and again in a June 2019 reproductive-safety advisory.45
What the evidence actually shows
Piracetam has genuine, narrow clinical utility — cortical myoclonus is the clearest case, and there are literatures on sickle-cell vaso-occlusion and possibly dyslexia. What it does not have is an evidence base for cognitive enhancement in healthy people. That evidence is essentially absent, and where piracetam has been tested in dementia and cognitive impairment, the Cochrane conclusion was that the evidence does not support its use. Doses in the literature run 1,200–4,800 mg/day, which is a pharmaceutical dose range, not a nutritional one.
Aniracetam (750–1,500 mg/day), oxiracetam (800–2,400 mg/day) and phenylpiracetam (100–200 mg/day) have less human data than piracetam does, mostly from old Italian and Eastern-European trials. Noopept is reported at 10–30 mg/day in Russian sources. The “1,000 times more potent than piracetam” figure that follows noopept everywhere is derived from rodent dose-equivalence — it describes how much of it you need to produce an effect in an animal model, not how well it works in a person. Potency is not efficacy. A compound can be a thousand times more potent than another compound at doing nothing useful.
Safety is characterized in proportion to the evidence, which is to say barely. Piracetam’s known profile includes headache, insomnia, agitation and weight gain, an antiplatelet effect that constitutes a real bleeding-risk interaction with anticoagulants, and renal clearance that requires dose reduction in kidney impairment. For noopept, the safety picture outside short Russian trials is largely unknown; there is no characterized drug-interaction profile at all, which is itself a reason to stay away. You cannot check a compound against your prescriptions when nobody has mapped how it behaves alongside them.
⚠️ Phenibut is the one that hurts people
Dependence and a severe withdrawal syndrome are well documented with phenibut. On the evidence we have, it is the single most dangerous item commonly sold in the “nootropics” category, and the risk is not a rare-reaction risk — it follows from regular use. If you are taking it daily and considering stopping, stopping abruptly is the part to be careful about. That is a conversation to have with a clinician, today, and it is a medical question rather than a supplement question.
What is actually in the bottle
The 2020 analysis by Cohen and colleagues in Neurology: Clinical Practice is the study to know here, and the assignment it was given is simple: buy US-sold “cognitive enhancement” supplements and analyse what they contain. It detected five unapproved drugs — omberacetam (noopept), aniracetam, phenibut, vinpocetine and picamilon. The drugs turned up frequently at doses above pharmacological norms, and frequently undeclared or mis-declared relative to the label.1 A separate published analysis documented the same problem for piracetam in products sold as supplements.6
Three consequences follow, and they are worth stating separately because readers usually only absorb the first.
- The label is not a contract. A product can contain a drug it does not name. Avoiding these compounds by reading ingredient lists is necessary and insufficient.
- The dose is not a dose. “Above pharmacological norms” means more than a prescriber would give, in a product with no dosing supervision and no adverse-event monitoring.
- The interaction risk is unknowable at the point of purchase. If you do not know what you took, neither does the person treating you afterwards.
Why the claim persists
Partly because the compounds do something. That is the uncomfortable part, and pretending otherwise is how a site loses the reader it most needs to reach. Phenibut is a GABAergic drug and people notice the effect. Racetams are pharmacologically active. The step people take next — from “I felt something” to “this works” — is the one the evidence does not support, and it is the same step that keeps every unproven intervention alive.
Partly because the community around these compounds is genuinely knowledgeable and genuinely helpful, which makes it persuasive in a way that advertising never manages.
Community reports — not trial data
Forum write-ups of racetam and noopept protocols are detailed, self-critical and often better documented than the marketing they replaced. They still are not evidence. Self-reported cognition is the least reliable measurement in this field: the same expectation effects that produce placebo responses in trials operate at full strength in someone who has read for a week about what a compound should do, and there is no control group in a thread. We take these reports seriously as a description of what people experience. We do not treat them as data about what the compounds do.
And partly because enforcement is complaint-driven. A warning letter binds one company. It does not clear a category, and it does not stop the same inventory reappearing under a new storefront. The FTC’s Prevagen case is the reference point for how long a claim can outlive its evidence: sued in January 2017, and only in December 2024 did a federal court, after a jury trial, order the marketer to stop making the deceptive memory and cognitive-improvement claims.789 Eight years is a long time to sell something.
What to do instead
If you are already taking one of these, the honest advice splits. For racetams and noopept, stopping is uncomplicated in the ordinary case, and telling your prescriber what you took matters more than the stopping itself — particularly if you take an anticoagulant, since piracetam has a real antiplatelet effect, or if you have any degree of kidney impairment. For phenibut, do not treat withdrawal as a self-managed project; the syndrome is documented and a clinician should be involved.
If you are shopping, the pattern to learn is the label. These compounds live inside long proprietary blends alongside other pharmacologically active ingredients at undisclosed doses — the same architecture we describe in nine ingredients that signal a bad brain supplement. Vinpocetine is the closest neighbour to this group and has its own FDA history worth reading.
And if the underlying question is what actually has evidence behind it, the answer is duller and shorter than this category promises. Our tier list ranks what has human trials and what does not; the case against brain supplements makes the broader argument; and how we rate evidence explains the standard we apply before anything gets a tier at all.
What would change our mind
On the legal question, an FDA determination reversing its position on any of these ingredients, or a court decision vacating it, would change the article — and we would date-stamp the change. On the evidence question, what would move us is unglamorous: a large, independently funded, placebo-controlled trial in healthy adults, pre-registered, with a cognitive primary endpoint and a duration measured in months. For noopept in particular, an independently conducted and reported trial outside Russia would be the first of its kind. Until one exists, “no adequate evidence” is not a hedge. It is the finding.
Frequently asked questions
Is it illegal to buy piracetam in the US?
These are not controlled substances, and possession is not the issue. The issue is that they cannot lawfully be sold as dietary supplements, which makes products containing them misbranded or adulterated — and that is what FDA’s warning letters address.2 The practical result is a market that exists without a legal basis for existing.
Isn’t phenibut just a supplement in some countries?
FDA’s published position is that phenibut does not meet the statutory definition of a dietary ingredient, and that supplements declaring it are misbranded.3 What another jurisdiction permits does not change either the US position or the documented dependence and withdrawal syndrome.
I take phenylpiracetam and I compete. Does that matter?
Yes. Phenylpiracetam is on WADA’s prohibited list. If you are tested in your sport, that is a decision with consequences well beyond the ones this article covers.
How would I know if a supplement contains one of these without saying so?
From the label alone, you would not — that is the finding of the Cohen analysis.1 What you can do is avoid the format in which these compounds hide: multi-ingredient proprietary blends with no per-ingredient doses, sold direct-to-consumer with no identifiable manufacturer address.
Does any of this apply to huperzine A?
Not in the same way. Huperzine A is plant-derived, is not on FDA’s exclusion list, and is widely sold. But it is a genuine reversible acetylcholinesterase inhibitor — the same pharmacological class as donepezil — and an approved drug in China. We discuss it; we do not recommend it, and it should never be stacked with a prescribed cholinesterase inhibitor.
Related reading
- Vinpocetine: FDA Says It’s Not a Dietary Ingredient
- Nine Ingredients That Signal a Bad Brain Supplement
- Do Nootropics Actually Work? An Honest Tier List
- Prevagen and the Apoaequorin Verdict
- Supplements That Cause Brain Fog
- How We Rate Evidence
Sources
- Cohen et al. — Five unapproved drugs found in cognitive enhancement supplements, Neurology: Clinical Practice (2020)
- FDA warning letter — Peak Nootropics LLC, aka Advanced Nootropics (5 February 2019)
- FDA — Phenibut in Dietary Supplements
- FDA — Vinpocetine in Dietary Supplements
- Federal Register — Request for Comment on the Status of Vinpocetine (2016)
- Analysis of piracetam in products sold as dietary supplements
- FTC — Statement on the FTC’s win in the lawsuit against the makers of Prevagen (December 2024)
- FTC — Prevagen complaint suggests mindfulness about memory claims (2017)
- FTC — Case file, Quincy Bioscience Holding Company (152-3206)
These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease.
This article is information, not medical advice. Talk to a doctor or pharmacist about your own situation, especially if you take prescription medication.